DCTH

Delcath Systems, Inc. is an interventional oncology company that develops and commercializes proprietary products for the treatment of primary and metastatic liver cancers. Its key offerings include the HEPZATO KIT™ (melphalan) for Injection and the CHEMOSAT® Hepatic Delivery System, which utilize a specialized procedure for hepatic delivery of chemotherapy. The company focuses on providing targeted therapies that enhance clinical outcomes while minimizing drug-related side effects, primarily serving patients with liver cancer across various geographies.